The newly released Global Swine Vaccine Market analysis report by Future Market Insights reveals that the global market for Swine Vaccine was held at around US$ 1.5 Billion in 2021, and is projected to grow at a CAGR of 5.8% from 2022 to 2032. The market is expected to surge with an absolute dollar opportunity of US$ 1.2 Billion. The projected market growth is expected to cross the historical CAGR of 4.9%.
The Inactivated Vaccines segment is likely to outpace all the other segments by growing at a CAGR of 5.9% from 2022 to 2032. Furthermore, Porcine Circovirus Type 2 was the top type segment in the global market. Revenue through this segment is expected to grow at a CAGR of 5.6% during the forecasted period.
| Attribute | Details |
|---|---|
| Global Swine Vaccines Market (2022) | US$ 1.6 Billion |
| Global Swine Vaccines Market (2032) | US$ 2.8 Billion |
| Global Swine Vaccines Market CAGR (2022 to 2032) | 5.8% |
| USA Swine Vaccines Market CAGR (2022 to 2032) | 6% |
| Key Companies Profiled |
|
The global market for Swine Vaccines is likely to be driven by increased demand for animal protein and surged Research and Development expenditure for vaccine innovation. Swine production is vital to global food security, agricultural countries, and domestic and international trade.
Contagious diseases have a global impact on pig health, as well as the swine industry's stability and production. As a result, increased swine disease prevalence is expected to boost the market in the coming years. Furthermore, leading players' increasing efforts in developing improved products for better diagnostics are expected to drive market expansion.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Swine Vaccine Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Swine Vaccine increased at a CAGR of around 4.9%, while the USA held the majority share of over 35% in the global market.
The market is being driven by increased disease prevalence, increased demand for animal protein, and increased Research and Development expenditure for vaccine innovation. Owing to this, the market for Swine Vaccines is projected to grow at a CAGR of 5.8% during the forecasted period.
Some of the key factors driving the growth of the Swine Vaccine market are the rising prevalence of swine diseases like PPV, Porcine Reproductive and Respiratory Syndrome (PRRS), and Classical Swine Fever, which are likely to cause economic losses due to their negative effects on reproduction and growth in pig farms.
Swine meat is vital for agriculture-based countries and it considerably affects domestic and international trade. Contagious diseases have a global impact on pig health, as well as the swine industry's stability and production. As a result, the increased prevalence of swine disease is expected to boost the market in the coming years.
Putting in place a pig vaccination program helps in protecting them from infectious diseases at every stage of their development. As a result, businesses are concentrating on providing immunization services to assist farmers to manage bacteria and viruses more effectively.
The rise in demand for animal protein, along with rising consumer preferences for a low-fat, high-protein diet like pork has resulted in a significant increase in animal protein consumption around the world.
Principal Consultant
APAC dominated the Swine Vaccine Market, where China led the regional demand. The consumption of beef and pork is higher in middle-income countries, particularly in Southeast Asia.
In addition, emerging infectious diseases in the region, such as swine fever, drive product demand even further. In India, CSF results in an annual loss of approximately 400 crores. As a result, the Indian government is placing a greater emphasis on the development of new vaccines. In October 2019, for example, the ICAR-Indian Veterinary Research Institute developed two diagnostic kits for Swine Control and Antigen Detection. These factors are leading to the expansion of the swine vaccine market in APAC.
USA Swine Vaccine Market Analysis
The market for swine vaccines in the USA is expected to reach a valuation of US$ 319 Million by 2032. With a CAGR of 6% during the forecast period, the market in the country is projected to gross an absolute dollar opportunity of US$ 137 Million.
UK Swine Vaccine Market Analysis
The market in the UK is projected to reach a valuation of US$ 112 Million by 2032. Growing at a CAGR of 6.1% during the forecast period, the market is expected to garner an absolute dollar opportunity of around US$ 48 Million.
China Swine Vaccine Market Analysis
In China, the market is projected to expand at a CAGR of 6.9% during 2022 - 2032. The market in the country is projected to reach US$ 1.1 Billion by 2032, grossing an absolute dollar opportunity of US$ 463 Million during the forecast period.
Japan Swine Vaccine Market Analysis
In Japan, the market is expected to reach a valuation of US$ 224 Million by 2032. With a CAGR of 7.5%, the market in the country is expected to gross an absolute dollar opportunity of US$ 96 Million by 2032.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market for Inactivated Vaccines is gaining the utmost traction and is expected to grow at a CAGR of 5.9% between 2022 and 2032. This increase in growth is attributable to easy availability, low cost, low risk of revert reaction of destroyed viruses, and fresh advances by key companies. For Example, PARVOVAX and PROGRESSIS vaccines were developed to fight against Porcine parvovirus and PRRS.
From 2022 to 2032, the recombinant vaccine category is projected to grow at the fastest rate. Because recombinants can carry many gene inserts, these vaccines are expected to aid in the vaccination of multiple viral strains.
Porcine Circovirus Type 2 is expected to dominate the global market and is expected to grow with a CAGR of 5.6% during the forecast period. PCV2 is the single-stranded DNA having the highest mutation and recombination rate among all single-stranded DNA viruses. It can be spread through an infected pig and is one of the most prevalent infectious agents affecting pig productivity. As a result, during the forecast period, it will contribute to a significant market share.
Some of the key competitors in the Swine Vaccine Market are Merck Animal Health, Ceva, Zoetis, Boehringer Ingelheim GmbH, Elanco, Indian Immunologicals Ltd., BiogénesisBagó, Phibro Animal Health, KM Biologics, and HIPRA.
Some of the recent developments in the Swine Vaccine Market are as follows:
Similarly, recent developments related to companies offering Swine Vaccine have been tracked by the team at Future Market Insights, which are available in the full report.
The Global Swine Vaccine Market is currently valued at US$ 1.5 billion and is expected to reach a valuation of US$ 1.6 billion by the end of 2022.
The Global Market for Swine Vaccine is expected to provide an Absolute Dollar Opportunity of US$ 1.2 billion during the period between 2022 and 2032 by growing at a CAGR of 5.8%.
The Inactivated Vaccines segment is likely to maintain its dominance and is expected to grow at a CAGR of 5.9% during the forecast period. This growth is attributable to easy availability, low cost, low risk of revert reaction of destroyed viruses, and fresh advances by key companies.
The key players operating in the Swine Vaccine market are Merck Animal Health, Ceva, Zoetis, Boehringer Ingelheim GmbH, Elanco, Indian Immunologicals Ltd., BiogénesisBagó, Phibro Animal Health, KM Biologics, and HIPRA.
1. Executive Summary | Swine Vaccine Market
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Demand
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Million)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background and Foundation Data Points
4.1. Global Market (US$ Million)
4.2. Market Opportunity Assessment (US$ Million)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Global Market Growth
4.5.3. Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Market Demand Analysis 2017 to 2021 and Forecast, 2022 to 2032
6.1. Historical Market Analysis, 2017 to 2021
6.2. Current and Future Market Projections, 2022 to 2032
6.3. Y-o-Y Growth Trend Analysis
7. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2021
7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Type, 2017 to 2021
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Type, 2022 to 2032
8.3.1. Swine Influenza
8.3.2. Classical Swine Fever
8.3.3. Porcine Parvovirus
8.3.4. Porcine Circovirus Type 2
8.3.5. M.Hyo
8.3.6. Actinobacillus Pleuropneumonia
8.3.7. Classical Swine Fever
8.3.8. Foot & Mouth Disease
8.3.9. Pseudorabies
8.3.10. PEDV
9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Product, 2017 to 2021
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2022 to 2032
9.3.1. Attenuated Live Vaccines
9.3.2. Inactivated Vaccines
9.3.3. Subunit Vaccines
9.3.4. DNA Vaccines
9.3.5. Recombinant Vaccines
9.4. Market Attractiveness Analysis By Product
10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
10.1. Introduction
10.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2021
10.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2022 to 2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. Asia Pacific
10.3.5. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
11.1. Introduction
11.2. Pricing Analysis
11.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032
11.4.1. By Country
11.4.1.1. United States of America
11.4.1.2. Canada
11.4.1.3. Rest of North America
11.4.2. By Type
11.4.3. By Product
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Type
11.5.3. By Product
12. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032
12.4.1. By Country
12.4.1.1. Brazil
12.4.1.2. Mexico
12.4.1.3. Rest of Latin America
12.4.2. By Type
12.4.3. By Product
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Type
12.5.3. By Product
13. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032
13.4.1. By Country
13.4.1.1. Germany
13.4.1.2. France
13.4.1.3. United Kingdom
13.4.1.4. Italy
13.4.1.5. Benelux
13.4.1.6. Nordic Countries
13.4.1.7. Rest of Europe
13.4.2. By Type
13.4.3. By Product
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Type
13.5.3. By Product
14. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032
14.4.1. By Country
14.4.1.1. China
14.4.1.2. Japan
14.4.1.3. South Korea
14.4.1.4. Rest of Asia Pacific
14.4.2. By Type
14.4.3. By Product
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Type
14.5.3. By Product
15. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
15.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032
15.4.1. By Country
15.4.1.1. GCC Countries
15.4.1.2. South Africa
15.4.1.3. Turkey
15.4.1.4. Rest of Middle East and Africa
15.4.2. By Type
15.4.3. By Product
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Type
15.5.3. By Product
16. Key Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.1.1. Market Value Proportion Analysis, By Key Countries
16.1.2. Global Vs. Country Growth Comparison
16.2. US Market Analysis
16.2.1. Value Proportion Analysis by Market Taxonomy
16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.2.2.1. By Type
16.2.2.2. By Product
16.3. Canada Market Analysis
16.3.1. Value Proportion Analysis by Market Taxonomy
16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.3.2.1. By Type
16.3.2.2. By Product
16.4. Mexico Market Analysis
16.4.1. Value Proportion Analysis by Market Taxonomy
16.4.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.4.2.1. By Type
16.4.2.2. By Product
16.5. Brazil Market Analysis
16.5.1. Value Proportion Analysis by Market Taxonomy
16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.5.2.1. By Type
16.5.2.2. By Product
16.6. Germany Market Analysis
16.6.1. Value Proportion Analysis by Market Taxonomy
16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.6.2.1. By Type
16.6.2.2. By Product
16.7. France Market Analysis
16.7.1. Value Proportion Analysis by Market Taxonomy
16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.7.2.1. By Type
16.7.2.2. By Product
16.8. Italy Market Analysis
16.8.1. Value Proportion Analysis by Market Taxonomy
16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.8.2.1. By Type
16.8.2.2. By Product
16.9. BENELUX Market Analysis
16.9.1. Value Proportion Analysis by Market Taxonomy
16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.9.2.1. By Type
16.9.2.2. By Product
16.10. UK Market Analysis
16.10.1. Value Proportion Analysis by Market Taxonomy
16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.10.2.1. By Type
16.10.2.2. By Product
16.11. Nordic Countries Market Analysis
16.11.1. Value Proportion Analysis by Market Taxonomy
16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.11.2.1. By Type
16.11.2.2. By Product
16.12. China Market Analysis
16.12.1. Value Proportion Analysis by Market Taxonomy
16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.12.2.1. By Type
16.12.2.2. By Product
16.13. Japan Market Analysis
16.13.1. Value Proportion Analysis by Market Taxonomy
16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.13.2.1. By Type
16.13.2.2. By Product
16.14. South Korea Market Analysis
16.14.1. Value Proportion Analysis by Market Taxonomy
16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.14.2.1. By Type
16.14.2.2. By Product
16.15. GCC Countries Market Analysis
16.15.1. Value Proportion Analysis by Market Taxonomy
16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.15.2.1. By Type
16.15.2.2. By Product
16.16. South Africa Market Analysis
16.16.1. Value Proportion Analysis by Market Taxonomy
16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.16.2.1. By Type
16.16.2.2. By Product
16.17. Turkey Market Analysis
16.17.1. Value Proportion Analysis by Market Taxonomy
16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.17.2.1. By Type
16.17.2.2. By Product
16.17.3. Competition Landscape and Player Concentration in the Country
17. Market Structure Analysis
17.1. Market Analysis by Tier of Companies
17.2. Market Concentration
17.3. Market Share Analysis of Top Players
17.4. Market Presence Analysis
17.4.1. By Regional footprint of Players
17.4.2. Product footprint by Players
18. Competition Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Competition Deep Dive
18.3.1. Merck Animal Health
18.3.1.1. Overview
18.3.1.2. Product Portfolio
18.3.1.3. Sales Footprint
18.3.1.4. Strategy Overview
18.3.2. Ceva
18.3.2.1. Overview
18.3.2.2. Product Portfolio
18.3.2.3. Sales Footprint
18.3.2.4. Strategy Overview
18.3.3. Zoetis
18.3.3.1. Overview
18.3.3.2. Product Portfolio
18.3.3.3. Sales Footprint
18.3.3.4. Strategy Overview
18.3.4. Boehringer Ingelheim GmbH
18.3.4.1. Overview
18.3.4.2. Product Portfolio
18.3.4.3. Sales Footprint
18.3.4.4. Strategy Overview
18.3.5. Elanco
18.3.5.1. Overview
18.3.5.2. Product Portfolio
18.3.5.3. Sales Footprint
18.3.5.4. Strategy Overview
18.3.6. Indian Immunologicals Ltd
18.3.6.1. Overview
18.3.6.2. Product Portfolio
18.3.6.3. Sales Footprint
18.3.6.4. Strategy Overview
18.3.7. BiogénesisBagó
18.3.7.1. Overview
18.3.7.2. Product Portfolio
18.3.7.3. Sales Footprint
18.3.7.4. Strategy Overview
18.3.8. Phibro Animal Health
18.3.8.1. Overview
18.3.8.2. Product Portfolio
18.3.8.3. Sales Footprint
18.3.8.4. Strategy Overview
18.3.9. KM Biologics
18.3.9.1. Overview
18.3.9.2. Product Portfolio
18.3.9.3. Sales Footprint
18.3.9.4. Strategy Overview
18.3.10. HIPRA
18.3.10.1. Overview
18.3.10.2. Product Portfolio
18.3.10.3. Sales Footprint
18.3.10.4. Strategy Overview
19. Assumptions and Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Swine Vaccine Market
